関連する実験動画
Updated: Jul 29, 2026

09:17
Psychophysical Tracking Method to Measure Taste Preferences in Children and Adults
Published on: July 16, 2016
まとめ
サクラロスは,下痢の経口補水療法には推奨されません. 口服用グルコース電解質溶液は,下痢性疾患の管理により効果的で安全です.
科学分野:
- クリニカル・メディシン 臨床医学
- 胃腸内科 胃腸内科
- 小児科は小児科です.
背景:
- 口腔補水療法 (ORT) は,下痢性疾患の管理に不可欠です.
- グルコースベースの口腔再水分化溶液 (ORS) は,非常に効果的です.
- ORTのためのサクラロースのような代替炭水化物の探求は重要です.
研究 の 目的:
- 経口下痢治療におけるグルコースの潜在的代替品としてのサクロースを評価する.
- 砂糖-電解質溶液とグルコース-電解質溶液の有効性と安全性を比較する.
主な方法:
- 下痢を患っている18人の患者は,サクロースと電解質の維持溶液を経口で摂取した.
- 流体バランス,プラズマ特異重量,便の減糖濃度などをモニタリングした.
- 治療の結果は,口服用グルコース-電解質溶液の既定データと比較した.
主要な成果:
- 18人の患者のうち15人がサクロース-電解質溶液で成功しました.
- 3人の患者は,流体損失と高血特異重量の大幅な増加を経験し,経口療法の中止を必要とした.
- テストされた12人の患者は,便の減糖糖の有意な濃度を示し,吸収不良を示した.
結論:
- サクラロスは,下痢における口腔再水分療法において,グルコースよりも効果が低く,潜在的に安全性が低い.
- 大量のの糖分を減らす存在は,砂糖の吸収が損なわれていることを示唆している.
- グルコースは,その優れた有効性と安全性プロファイルのために,下痢性疾患における口腔再水分化溶液の好ましい炭水化物であり続けています.
関連する概念動画
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
Drugs for Treatment of Diarrhea-Predominant IBS
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Drugs for Treatment of Constipation-Predominant IBS
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
Oral Hypoglycemic Agents: Sulfonylureas
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Acarbose and miglitol are typically...
Cholera
Cholera is an acute gastrointestinal disease caused by the Gram-negative bacterium Vibrio cholerae. It is transmitted primarily via the fecal-oral route through the ingestion of contaminated water or food.Vibrio cholerae is a motile, Gram-negative bacterium of the family Vibrionaceae, primarily associated with waterborne outbreaks in areas with inadequate sanitation. Although over 200 serogroups of V. cholerae exist, only O1 and O139 are responsible for epidemic cholera. The O1 serogroup,...

